Cytek Biosciences Stock Alpha and Beta Analysis
| CTKB Stock | USD 6.53 0.03 0.46% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cytek Biosciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cytek Biosciences over a specified time horizon. Remember, high Cytek Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cytek Biosciences' market risk premium analysis include:
Beta 4.73 | Alpha (0.19) | Risk 5.68 | Sharpe Ratio 0.0778 | Expected Return 0.44 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Cytek |
Cytek Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cytek Biosciences market risk premium is the additional return an investor will receive from holding Cytek Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cytek Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cytek Biosciences' performance over market.| α | -0.19 | β | 4.73 |
Cytek Biosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Cytek Biosciences' Buy-and-hold return. Our buy-and-hold chart shows how Cytek Biosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Cytek Biosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Cytek Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cytek Biosciences shares will generate the highest return on investment. By understating and applying Cytek Biosciences stock market price indicators, traders can identify Cytek Biosciences position entry and exit signals to maximize returns.
Cytek Biosciences Return and Market Media
The median price of Cytek Biosciences for the period between Sat, Aug 31, 2024 and Fri, Nov 29, 2024 is 5.32 with a coefficient of variation of 12.44. The daily time series for the period is distributed with a sample standard deviation of 0.69, arithmetic mean of 5.54, and mean deviation of 0.54. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 200000 shares by Wenbin Jiang of Cytek Biosciences subject to Rule 16b-3 | 09/13/2024 |
2 | Cytek Biosciences, Inc.s Intrinsic Value Is Potentially 99 percent Above Its Share Price | 09/18/2024 |
3 | Deerfield Management Company L.P. Series C Acquires Shares of 155,759 Cytek Biosciences, Inc. - MarketBeat | 09/27/2024 |
4 | Acquisition by Allen Poirson of 2503 shares of Cytek Biosciences subject to Rule 16b-3 | 10/11/2024 |
5 | Acquisition by Imper Vera of 15706 shares of Cytek Biosciences subject to Rule 16b-3 | 10/15/2024 |
6 | Acquisition by Paul Williams of 8840 shares of Cytek Biosciences subject to Rule 16b-3 | 10/18/2024 |
7 | Codexis Reports Q3 Loss, Tops Revenue Estimates | 10/31/2024 |
8 | Cytek Biosciences, Inc. Q3 Earnings and Revenues Beat Estimates | 11/05/2024 |
9 | Cytek Biosciences Announces Quarterly Earnings Results | 11/06/2024 |
10 | Cytek Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter | 11/07/2024 |
11 | Acquisition by Holder Michael of 2181 shares of Cytek Biosciences subject to Rule 16b-3 | 11/18/2024 |
12 | Disposition of 1235 shares by Barnett Valerie of Cytek Biosciences at 6.03 subject to Rule 16b-3 | 11/20/2024 |
13 | Acquisition by Barnett Valerie of 2016 shares of Cytek Biosciences subject to Rule 16b-3 | 11/27/2024 |
About Cytek Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cytek or other stocks. Alpha measures the amount that position in Cytek Biosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 16.09 | 13.12 | 27.57 | 28.95 | Days Of Inventory On Hand | 240.59 | 278.71 | 265.83 | 195.16 |
Cytek Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Cytek Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cytek Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Cytek Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Cytek Biosciences. Please utilize our Beneish M Score to check the likelihood of Cytek Biosciences' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Cytek Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Cytek Biosciences Backtesting, Cytek Biosciences Valuation, Cytek Biosciences Correlation, Cytek Biosciences Hype Analysis, Cytek Biosciences Volatility, Cytek Biosciences History and analyze Cytek Biosciences Performance. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Cytek Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.